COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01263366
Recruitment Status : Terminated (Enrollment issues)
First Posted : December 20, 2010
Last Update Posted : April 19, 2013
University of Wisconsin, Madison
Information provided by (Responsible Party):
ProCertus BioPharm, Inc

Brief Summary:

This study, a nonrandomized open-label Phase I safety and exploratory study, will evaluate the safety of topical norepinephrine in post-surgical breast cancer patients who are undergoing radiation therapy.

The study will also provide information about whether topical norepinephrine can prevent or decrease the severity of the radiation dermatitis experienced by these patients.

Condition or disease Intervention/treatment Phase
Radiodermatitis Drug: Norepinephrine Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Exploratory Study of Topical Norepinephrine in Post-Surgical Breast Cancer Patients Receiving Radiotherapy
Study Start Date : January 2011
Actual Primary Completion Date : April 2013
Actual Study Completion Date : April 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Norepinephrine Drug: Norepinephrine
Approximately 1.6 or 4.6 mL of a 400 mM norepinephrine solution will be applied topically to a portion of the radiation treatment field prior to each radiation treatment (20-33 treatments)
Other Name: Noradrenaline

Primary Outcome Measures :
  1. Safety of daily topical application of norepinephrine to the radiation field [ Time Frame: Safety will be assessed during the study (5-7 weeks) and at follow-up visits approximately 1, 2 and 4 weeks after the end of the treatment period. ]
    The primary safety hypothesis is that there will be little or no skin irritation associated with the application of the topical norepinephrine and no systemic effects secondary to transdermal absorption.

Secondary Outcome Measures :
  1. Efficacy of daily topical application of norepinephrine to the radiation field [ Time Frame: Efficacy will be assessed during the study (5-7 weeks) and at follow-up visits approximately 1, 2 and 4 weeks after the end of the treatment period. ]
    The primary efficacy hypothesis is that the portion of the radiation site that is treated with topical norepinephrine immediately prior to daily radiotherapy will have less severe radiation dermatitis than the adjacent untreated portion of the radiation site.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Eligibility Criteria

Subjects must:

  • be ≥ age 18 years of age with a documented pathological diagnosis of Stage Ia (T1, N0, M0), Stage Ib (T0 or 1, N1mic, M0) or Stage IIa (T<3cm, N0, M0) infiltrating ductal or lobular carcinoma of the breast or ductal carcinoma in situ (DCIS).
  • be post-surgical patients scheduled to be treated with at least 40 to 50.4 Gy to the whole breast and axilla using either standard or hypofractionated radiation techniques . An additional 10-16 Gy boost to the lumpectomy region may also be delivered. All radiation treatment is to be delivered based on standard CT planning.
  • have the ability to understand the informed consent document.
  • be able to comply with protocol schedule.
  • have a negative serum pregnancy test (within 7 days prior to starting radiation therapy), if a female of child bearing potential.
  • consent to utilize medically acceptable methods of contraception throughout the study period if of child-bearing potential.

Exclusion Criteria


  • with unhealed surgical wounds or scars in the study treatment area (axilla).
  • with underlying active untreated cardiac disease (e.g. arrhythmia).
  • with generalized skin disorders that have required treatment within the past 6 months.
  • with connective tissue disorders.
  • with rashes, ulcerations, or poorly healed scars in the study drug application area (axilla).
  • with a known allergy to norepinephrine.
  • with known uncontrolled hypertension (repeatedly elevated BP; systolic BP >139 or diastolic BP >89).
  • with a known clinically significant abnormal ECG within the past 6 months.
  • receiving MAO inhibitors or antidepressants (triptyline or imipramine types).
  • who are pregnant or breastfeeding.
  • with lymphovascular space invasion on pathology.
  • with dermal lymphatic invasion on pathology.
  • with proximity of the tumor to the overlying skin as evidenced by a distance of less than 5 mm on US or MRI (if performed) and within 2 cm of the anticipated application field
  • diagnosis of inflammatory breast cancer.
  • receiving chemotherapy other than Herceptin concurrent with the radiation.
  • with previous radiation to the breast to be treated.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01263366

Layout table for location information
United States, Wisconsin
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
ProCertus BioPharm, Inc
University of Wisconsin, Madison
Layout table for investigator information
Principal Investigator: James F Cleary, MBBS University of Wisconsin, Madison
Study Chair: Bethany M Anderson, MD University of Wisconsin, Madison
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: ProCertus BioPharm, Inc Identifier: NCT01263366    
Other Study ID Numbers: PC-4
First Posted: December 20, 2010    Key Record Dates
Last Update Posted: April 19, 2013
Last Verified: April 2013
Keywords provided by ProCertus BioPharm, Inc:
Radiation Dermatitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases
Radiation Injuries
Wounds and Injuries
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents